Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop

National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
Psychiatric illnesses – such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) – are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients’ disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.
Published in:
National Academies of Sciences, Engineering, and Medicine

More Publications

August 1, 2023

Journal of Psychopharmacology

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

July 6, 2023

Gerontology and Geriatric Medicine

Caring for Dementia Caregivers: Understanding Caregiver Stress During the COVID-19 Pandemic

May 19, 2023

Nature Reviews Neurology

Global synergistic actions to improve brain health for human development

April 20, 2023

Nature Mental Health

Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD

February 21, 2023

Translational Psychiatry

Screening for PTSD and TBI in Veterans using Routine Clinical Laboratory Blood Tests

February 13, 2023

Frontiers in Aging Neuroscience

Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs